Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.
- Resource Type
- Academic Journal
- Authors
- Shah S; Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Kline EG; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Haidar G; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Squires KM; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Pogue JM; Department of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.; McCreary EK; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Ludwig J; Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Clarke LG; Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Stellfox M; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Van Tyne D; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.; Shields RK; Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA.
- Source
- Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
- Subject
- Language
- English
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs. 10%; P=0.002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)